Clinical trial NCT02259764: Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of KUC 7483 CL Tablets in Healthy Male Volunteers
Official title: Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses (400, 440 and 480 mg) of KUC 7483 CL Tablets in Healthy Male Volunteers. A Double-blind at Each Dose Level, Randomised, Placebo Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2014-10-09
Enrollment: 24
Sex: MALE
Minimum age (years): 30
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Study to investigate safety, tolerability and pharmacokinetics of KUC 7483 CL


Eligibility criteria: Inclusion Criteria:

1. Healthy males according to the following criteria:

   Based upon a complete medical history, including the physical examination, vital signs (BP, PR), 12-lead ECG, clinical laboratory tests

   1.1 No finding deviating from normal and of clinical relevance

   1.2 No evidence of a clinically relevant concomitant disease
2. Age ≥ 30 and Age ≤ 60 years
3. BMI ≥ 18.5 and BMI ≤ 29.9 kg/m2 (Body Mass Index)
4. Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation

Exclusion Criteria:

* Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
* Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
* History of relevant orthostatic hypotension, fainting spells or blackouts
* Chronic or relevant acute infections
* History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
* Intake of drugs with a long half-life (\> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
* Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
* Participation in another trial with an investigational drug within two months prior to administration or during the trial
* Smoker (\> 10 cigarettes or \> 3 cigars of \> 3 pipes/day)
* Inability to refrain from smoking on trial days
* Alcohol abuse (more than 60 g/day)
* Drug abuse
* Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
* Excessive physical activities (within one week prior to administration or during the trial)
* Any laboratory value outside the reference range of clinical relevance

The clinical relevance of study parameters will be assessed by the investigator or his deputy

Primary outcomes:
measure: Number of subjects with abnormal findings in physical examination
timeFrame: up to 8 days after last drug administration
measure: Number of subjects with abnormal changes in laboratory parameters
timeFrame: up to 8 days after last drug administration
measure: Number of subjects with clinically significant changes in vital signs
timeFrame: up to 8 days after last drug administration
measure: Number of subjects with clinically significant changes in 12-lead ECG (electrocardiogram)
timeFrame: up to 8 days after last drug administration
measure: Number of subjects with adverse events
timeFrame: up to 8 days after last drug administration
measure: Assessment of tolerability by investigator on a 4-point scale
timeFrame: 8 days after last drug administration
Secondary outcomes:
measure: Cmax (maximum measured concentration of the analyte in plasma)
timeFrame: up to 48 hours after drug administration
measure: tmax (time from dosing to the maximum concentration of the analyte in plasma)
timeFrame: up to 48 hours after drug administration
measure: AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)
timeFrame: up to 48 hours after drug administration
measure: AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)
timeFrame: up to 48 hours after drug administration
measure: λ z (terminal rate constant of the analyte in plasma)
timeFrame: up to 48 hours after drug administration
measure: t1/2 (terminal half-life of the analyte in plasma)
timeFrame: up to 48 hours after drug administration
measure: MRTpo (mean residence time of the analyte in the body after oral administration)
timeFrame: up to 48 hours after drug administration
measure: CL/F (apparent clearance of the analyte in the plasma after extravascular administration)
timeFrame: up to 48 hours after drug administration
measure: Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)
timeFrame: up to 48 hours after drug administration
measure: Aet1-t2 (amount of the analyte that is eliminated in urine from the time point t1 until time point t2)
timeFrame: up to 48 hours after drug administration
measure: fet1-t2 (fraction of administered drug excreted unchanged in urine from the time point t1 until time point t2)
timeFrame: up to 48 hours after drug administration
measure: CLR,t1-t2 (renal clearance of the analyte determined from the time point t1 until time point t2)
timeFrame: up to 48 hours after drug administration
Other outcomes:
Locations:
Study officials:
References: